To know more about 57357 Covid-19 Clinic
Click here

In cooperation with Tulane University, USA, a 57357 study team unravels the reasons behind chemotherapy resistance in papillary thyroid cancer patients

    Published in the American Journal of Cancer Research Impact factor: 6.1 It is known that papillary thyroid cancer, PTC, is an aggressive type of cancer with survival rate of 35%. A research team lead by Dr. Sameh Magdeldin, head of 57357’s proteomics and metabolomics unit discovered one of the reasons for drug resistance in case … Continued

Published in the American Journal of Cancer Research

Impact factor: 6.1

It is known that papillary thyroid cancer, PTC, is an aggressive type of cancer with survival rate of 35%. A research team lead by Dr. Sameh Magdeldin, head of 57357’s proteomics and metabolomics unit discovered one of the reasons for drug resistance in case of PTC. It was found that PTC patients receiving chemotherapy may develop resistance to chemotherapy due to the changes in the cancer cells which produce two protein complex ARP2/3. The research was done using a state of the art technology, the mass spectrometer which is the only one in Egypt.

According to Dr. Magdeldin, this problem can be solved in the future by giving the patient medications to counteract the protein complex, or by changing the type of chemotherapy.

The research was performed in cooperation with Tulane University, USA, and was published in the American Journal of Cancer Research.